Home › NDC Lookup › RxCUI directory › RxCUI 2380551

12 HR fostemsavir 600 MG Extended Release Oral Tablet [Rukobia] — RxCUI 2380551

RxNorm drug concept · Semantic branded drug
RxCUI 2380551 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2380551
Official name12 HR fostemsavir 600 MG Extended Release Oral Tablet [Rukobia]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRukobia 600 MG 12 HR Extended Release Oral Tablet; Rukobia 600 MG 12HR Extended Release Oral Tablet; 12 HR fostemsavir 600 MG (equivalent to 725 MG fostemsavir tromethamine) Extended Release Oral Tablet [Rukobia]
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)2,430 prescriptions · 21 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Fostemsavir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Rukobia is designed for people who have been on HIV treatment for a long time and whose virus has become resistant to many other drugs — or who couldn't tolerate those other option...
  • Why am I being prescribed Rukobia instead of one of the more common HIV medications?
  • Yes, you can take it either way — with or without food. That said, a very high-fat meal can noticeably increase the amount of medicine that gets into your bloodstream, so try to be...
  • Can I take Rukobia with or without food?
📖 Read our full Fostemsavir guide →

🕸️ Concept Web — How 12 HR fostemsavir 600 MG Extended Release Oral T... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12 HR fostemsavir 600 MG Extended Release Oral Tablet [Rukobia] RxCUI 2380551

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Fostemsavir 2380373
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Rukobia 2380540
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fostemsavir Extended Release Oral Tablet 2380538
    • Fostemsavir Oral Product 2380536
    • Fostemsavir Pill 2380537
    • Fostemsavir Extended Release Oral Tablet [Rukobia] 2380542
    • Rukobia Oral Product 2380543
    • Rukobia Pill 2380544
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Fostemsavir 600 MG [Rukobia] SBDC · 2380550
  • Fostemsavir Extended Release Oral Tablet [Rukobia] SBDF · 2380542
  • Rukobia Oral Product SBDG · 2380543
  • Rukobia Pill SBDG · 2380544
  • Rukobia BN · 2380540

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2380551 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49702-0250-18 1 BOTTLE in 1 CARTON (49702-250-18) / 60 TABLET, FILM COATE... Rukobia ViiV Healthcare Company 2020-07-02
Observed labelers: ViiV Healthcare Company (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$156.8670
Range $156.8670–$156.8670 · middle 50% $156.8670–$156.8670 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.